Chart-Typ:
Zeitraum:
| ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen |
| ADMA Biologics, Inc.: ADMA Biologics Addresses Misleading Short-Seller Report | RAMSEY, N.J. and BOCA RATON, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated... ► Artikel lesen |
| Alamar Biosciences Prices Upsized IPO At $17/shr; Raises $191.3 Mln | WASHINGTON (dpa-AFX) - Alamar Biosciences, Inc. Common Stock (ALMR) on Friday announced the pricing of its upsized initial public offering of 11.25 million shares of stock at $17 per share.The... ► Artikel lesen |
| Alamar Biosciences, Inc.: Alamar Biosciences Launches NULISAseq Neuro 220 Panel, its largest precision proteomics panel with the sensitivity and specificity to advance neurological disease research | New panel expands coverage for Alzheimer's and Parkinson's diseases including 15 new biomarkers developed with support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and 12 assays... ► Artikel lesen |
| Alamar Biosciences, Inc.: Alamar Biosciences Announces Launch of NULISAqpcr AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research | FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor | FDA assigned PDUFA target action date of January 29, 2027 No advisory committee meeting expected BOSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy | Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed... ► Artikel lesen |
| Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KAILERA THERAPEUTICS INC finden Sie auf Wallstreet Online.